Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-26T13:10:36.976Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term inhaled iloprost use in children with pulmonary arterial hypertension

Published online by Cambridge University Press:  09 November 2011

Dursun Alehan ,
Işıl Yıldırım ,
Murat Şahin ,
Süheyla Özkutlu ,
Sema Özer  and
Tevfik Karagöz
Dursun Alehan*
Affiliation:
Section of Cardiology, Faculty of Medicine, Department of Pediatrics, Hacettepe University, Sıhhıye, Ankara, Turkey
Işıl Yıldırım
Affiliation:
Section of Cardiology, Faculty of Medicine, Department of Pediatrics, Hacettepe University, Sıhhıye, Ankara, Turkey
Murat Şahin
Affiliation:
Section of Cardiology, Faculty of Medicine, Department of Pediatrics, Hacettepe University, Sıhhıye, Ankara, Turkey
Süheyla Özkutlu
Affiliation:
Section of Cardiology, Faculty of Medicine, Department of Pediatrics, Hacettepe University, Sıhhıye, Ankara, Turkey
Sema Özer
Affiliation:
Section of Cardiology, Faculty of Medicine, Department of Pediatrics, Hacettepe University, Sıhhıye, Ankara, Turkey
Tevfik Karagöz
Affiliation:
Section of Cardiology, Faculty of Medicine, Department of Pediatrics, Hacettepe University, Sıhhıye, Ankara, Turkey
*
Correspondence to: Dr D. Alehan, MD, Section of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Sıhhıye, Ankara 06100, Turkey. Tel: +90 312 305 1157; Fax: +90 312 309 0220; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

We performed a retrospective analysis of patients with pulmonary arterial hypertension receiving inhaled iloprost in a single centre to evaluate long-term tolerability, safety, and efficacy of chronic inhaled iloprost therapy in children.

Methods

A total of 20 patients with either idiopathic or associated pulmonary arterial hypertension were treated with iloprost between April, 2003 and January, 2010. The median age and weight of the patients were 3.8 years – ranging from 4 months to 19 years – and 12.3 kilograms – ranging from 4 to 73 kilograms – respectively. Pulmonary arterial hypertension was idiopathic or hereditary in eight patients (40%) and associated with congenital cardiac disease in 12 patients (60%).

Results

Of the 20 patients, 15 had combined therapy – 12 patients with two and three patients with three different classes of drugs. In all, six patients died during follow-up. The median follow-up time was 18 months, ranging from 6 to 74 months. The 6-minute walking test was performed in 7 out of 20 patients at baseline and on follow-up. The median 6-minute walking test increased from 420 to 490 metres after iloprost therapy (p = 0.028). After initiation of iloprost therapy, one patient complained of headache and another had a rash around his mouth, none necessitating discontinuation of therapy. Overall compliance with inhaled iloprost was good.

Conclusion

Pulmonary hypertension is associated with significant morbidity and mortality. Careful assessment of each patient and timely combination of specific vasodilator therapy is needed to improve clinical outcomes. This study suggests that inhaled iloprost, with or without concomitant endotelin receptor antagonist and/or phosphodiesterase inhibitor, is safe and efficacious for treatment of pulmonary arterial hypertension in children.

Keywords

Inhaled iloprostchildrenpulmonary arterial hypertension
Type
Original Article
Information
Cardiology in the Young , Volume 22 , Issue 4 , August 2012 , pp. 396 - 403
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Galie, N, Hoeper, MM, Humbert, M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537.Google Scholar
2. Tissot, C, Beghetti, M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 2009; 5: 325–331.Google ScholarPubMed
3. Yung, D, Widlitz, AC, Rosenzweig, EB, Kerstein, D, Maislin, G, Barst, RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660–665.CrossRefGoogle ScholarPubMed
4. Barst, RJ, Rubin, LJ, Long, WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302.CrossRefGoogle Scholar
5. Barst, RJ, Galie, N, Naeije, R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195–1203.CrossRefGoogle ScholarPubMed
6. Galie, N, Humbert, M, Vachiery, JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496–1502.CrossRefGoogle ScholarPubMed
7. Ivy, DD, Doran, AK, Smith, KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161–169.CrossRefGoogle Scholar
8. Galie, N, Olschewski, H, Oudiz, RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.CrossRefGoogle ScholarPubMed
9. Galie, N, Rubin, L, Hoeper, M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.CrossRefGoogle ScholarPubMed
10. Barst, RJ, Langleben, D, Badesch, D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049–2056.CrossRefGoogle ScholarPubMed
11. Galie, N, Ghofrani, HA, Torbicki, A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.CrossRefGoogle ScholarPubMed
12. Galie, N, Brundage, BH, Ghofrani, HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.CrossRefGoogle ScholarPubMed
13. Olschewski, H, Rohde, B, Behr, J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294–1304.CrossRefGoogle ScholarPubMed
14. Limsuwan, A, Wanitkul, S, Khosithset, A, Attanavanich, S, Samankatiwat, P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008; 129: 333–338.CrossRefGoogle ScholarPubMed
15. Hallioglu, O, Dilber, E, Celiker, A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92: 1007–1009.CrossRefGoogle ScholarPubMed
16. Rimensberger, PC, Spahr-Schopfer, I, Berner, M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544–548.CrossRefGoogle ScholarPubMed
17. Hsu, HH, Rubin, LJ. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2005; 6: 1921–1930.CrossRefGoogle ScholarPubMed
18. Olschewski, H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 2009; 18: 29–34.CrossRefGoogle ScholarPubMed